These results are consistent with our previous findings on the synergistic interaction of gemcitabine with other LDH-A inhibitors in preclinical models of pancreatic cancer and MPM.17,18 Further studies are warranted to unravel the molecular mechanisms underlying this synergistic interaction. The gene discussed is LDHA; the disease is familial pancreatic carcinoma.